Molecular targets for radiation oncology in prostate cancer
Recent selected development of the molecular science of Prostate cancer (PrCa) biology and radiation oncology is reviewed. We present potential targets for molecular integration treatment strategies with radiation therapy (RT), and highlight potential strategies for molecular treatment in combinati...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2011-07-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fonc.2011.00017/full |
id |
doaj-a3c583dd47a44000bad4fc4cac3fb974 |
---|---|
record_format |
Article |
spelling |
doaj-a3c583dd47a44000bad4fc4cac3fb9742020-11-24T22:10:11ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2011-07-01110.3389/fonc.2011.0001710783Molecular targets for radiation oncology in prostate cancerTao eWang0Lucia R Languino1Jane eLian2Gary eStein3Michael eBlute4Thomas J FitzGerald5University of Massachusetts Medical SchoolThomas Jefferson UniversityUniversity of Massachusetts Medical SchoolUniversity of Massachusetts Medical SchoolUniversity of Massachusetts Medical SchoolUniversity of Massachusetts Medical SchoolRecent selected development of the molecular science of Prostate cancer (PrCa) biology and radiation oncology is reviewed. We present potential targets for molecular integration treatment strategies with radiation therapy (RT), and highlight potential strategies for molecular treatment in combination with RT for patient care. We provide a synopsis of the information to date regarding molecular biology of PrCa, and potential integrated research strategy for improved treatment of PrCa. Many patients with early stage disease at presentation can be treated effectively with androgen ablation treatment, surgery or RT. However, a significant portion of men are diagnosed with advanced stage/high risk disease and these patients progress despite curative therapeutic intervention. Unfortunately, management options for these patients are limited and are not always successful including treatment for hormone refractory (HR) disease. In this review, we focus on molecules of extracellular matrix component, apoptosis, androgen receptor, RUNX and DNA methylation. Expanding our knowledge of the molecular biology of prostate cancer will permit the development of novel treatment strategies integrated with radiation therapy to improve patient outcomehttp://journal.frontiersin.org/Journal/10.3389/fonc.2011.00017/fullApoptosisDNA MethylationRadiationARECM/integrinPrCa |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Tao eWang Lucia R Languino Jane eLian Gary eStein Michael eBlute Thomas J FitzGerald |
spellingShingle |
Tao eWang Lucia R Languino Jane eLian Gary eStein Michael eBlute Thomas J FitzGerald Molecular targets for radiation oncology in prostate cancer Frontiers in Oncology Apoptosis DNA Methylation Radiation AR ECM/integrin PrCa |
author_facet |
Tao eWang Lucia R Languino Jane eLian Gary eStein Michael eBlute Thomas J FitzGerald |
author_sort |
Tao eWang |
title |
Molecular targets for radiation oncology in prostate cancer |
title_short |
Molecular targets for radiation oncology in prostate cancer |
title_full |
Molecular targets for radiation oncology in prostate cancer |
title_fullStr |
Molecular targets for radiation oncology in prostate cancer |
title_full_unstemmed |
Molecular targets for radiation oncology in prostate cancer |
title_sort |
molecular targets for radiation oncology in prostate cancer |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Oncology |
issn |
2234-943X |
publishDate |
2011-07-01 |
description |
Recent selected development of the molecular science of Prostate cancer (PrCa) biology and radiation oncology is reviewed. We present potential targets for molecular integration treatment strategies with radiation therapy (RT), and highlight potential strategies for molecular treatment in combination with RT for patient care. We provide a synopsis of the information to date regarding molecular biology of PrCa, and potential integrated research strategy for improved treatment of PrCa. Many patients with early stage disease at presentation can be treated effectively with androgen ablation treatment, surgery or RT. However, a significant portion of men are diagnosed with advanced stage/high risk disease and these patients progress despite curative therapeutic intervention. Unfortunately, management options for these patients are limited and are not always successful including treatment for hormone refractory (HR) disease. In this review, we focus on molecules of extracellular matrix component, apoptosis, androgen receptor, RUNX and DNA methylation. Expanding our knowledge of the molecular biology of prostate cancer will permit the development of novel treatment strategies integrated with radiation therapy to improve patient outcome |
topic |
Apoptosis DNA Methylation Radiation AR ECM/integrin PrCa |
url |
http://journal.frontiersin.org/Journal/10.3389/fonc.2011.00017/full |
work_keys_str_mv |
AT taoewang moleculartargetsforradiationoncologyinprostatecancer AT luciarlanguino moleculartargetsforradiationoncologyinprostatecancer AT janeelian moleculartargetsforradiationoncologyinprostatecancer AT garyestein moleculartargetsforradiationoncologyinprostatecancer AT michaeleblute moleculartargetsforradiationoncologyinprostatecancer AT thomasjfitzgerald moleculartargetsforradiationoncologyinprostatecancer |
_version_ |
1725808809863020544 |